Literature DB >> 6232321

Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.

M R Daha, A M Deelder, L A Van Es.   

Abstract

Three IgM mouse monoclonal antibodies (MoAb), 5B5-A, 2D2-B, and 5B12-A, were prepared by fusion of spleen cells from mice immunized with human B with the SP 2/0 myeloma cell line. They were assessed for their effect on cell-bound and fluid-phase amplification convertases of complement (C) with purified proteins in vitro. 5B5-A and 2D2-B were similar in their effects on cell-bound preformed C3bBb in that they bound to cell-bound C3bBb, stabilized the C3bBb convertase, and rendered the C3bBb convertase relatively resistant to the plasma protein H. These two MoAb were also able to enhance C3 consumption in vitro in reaction mixtures containing C3b, C3, B, and D. At the same time, they presumably stabilized the C3 convertase and caused relative sparing of B hemolytic activity in the reaction mixtures. In contrast, 5B12-A, which also bound to Bb and C3bBb, did not induce any stabilization, but rather caused accelerated decay of cell-bound C3bBb. These results indicate that MoAb against B can have C3NeF-like activity. On the other hand, not all MoAb against B have stabilizing activity on the C3bBb convertase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232321

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.

Authors:  T E Mollnes; Y C Ng; D K Peters; T Lea; J Tschopp; M Harboe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

2.  Murine monoclonal anti-Ba antibody that enhances haemolytic activity of factor B.

Authors:  E Tanaka; K Hong; T Kinoshita; Y Takata; H Kozono; J Takeda; A Yoden; K Inoue
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

3.  Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.

Authors:  Y Tanuma; H Ohi; M Hatano
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

4.  Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B.

Authors:  C W Clardy
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.